Who
Yezan Munther Haddadin
Director
Company insider
Files Form 4 as: Director, Outlook Therapeutics.
In numbers
- Trades disclosed
- 30
- Buys
- 8
- Sells
- 0
- Bought
- $183K
- Sold
- $0
- Companies
- 1
- Companies where not an officer
- 1
- First trade
- 31 Oct 2017
- Last trade
- 2 Jun 2026
- Last filed
- 3 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 2 Jun 2026filed 3 Jun 2026 | OTLK Outlook TherapeuticsBiotechnology | SEC FORM 4 Bought | $24K29,000 at $0.8326 | filing |
| 2 Jun 2026filed 3 Jun 2026 | OTLK Outlook TherapeuticsBiotechnology | SEC FORM 4 Bought | $24K29,000 at $0.83 | filing |
| 26 May 2026filed 27 May 2026 | OTLK Outlook TherapeuticsBiotechnology | SEC FORM 4 Bought | $15K34,000 at $0.44 | filing |
| 26 May 2026filed 27 May 2026 | OTLK Outlook TherapeuticsBiotechnology | SEC FORM 4 Bought | $15K34,000 at $0.44 | filing |
| 3 Oct 2025filed 3 Oct 2025 | OTLK Outlook Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —95,969 at $0.00 | filing |
| 1 Oct 2025filed 3 Oct 2025 | OTLK Outlook Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —286,734 at $0.00 | filing |
| 3 Oct 2024filed 3 Oct 2024 | OTLK Outlook Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —19,771 at $0.00 | filing |
| 1 Oct 2024filed 3 Oct 2024 | OTLK Outlook Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —56,636 at $0.00 | filing |
| 1 Oct 2024filed 3 Oct 2024 | OTLK Outlook Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —132,293 at $0.00 | filing |
| 28 Mar 2024filed 29 Mar 2024 | OTLK Outlook TherapeuticsBiotechnology | SEC FORM 4 Bought | $22K1,881.71 at $11.82 | filing |
| 7 Mar 2024filed 8 Mar 2024 | OTLK Outlook Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —94,441 at $0.00 | filing |
| 4 Oct 2023filed 5 Oct 2023 | OTLK Outlook Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —358,337 at $0.00 | filing |
| 29 Mar 2023filed 31 Mar 2023 | OTLK Outlook Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —41,065 at $0.00 | filing |
| 7 Oct 2022filed 11 Oct 2022 | OTLK Outlook TherapeuticsBiotechnology | SEC FORM 4 Bought | $4,5723,600 at $1.27 | filing |
| 6 Oct 2022filed 11 Oct 2022 | OTLK Outlook TherapeuticsBiotechnology | SEC FORM 4 Bought | $38K29,743 at $1.29 | filing |
| 5 Oct 2022filed 7 Oct 2022 | OTLK Outlook Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —71,998 at $0.00 | filing |
| 23 Mar 2022filed 24 Mar 2022 | OTLK Outlook Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —21,878 at $0.00 | filing |
| 2 Dec 2021filed 2 Dec 2021 | OTLK Outlook TherapeuticsBiotechnology | SEC FORM 4 Bought | $14K10,000 at $1.39 | filing |
| 5 Oct 2021filed 7 Oct 2021 | OTLK Outlook Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —47,335 at $0.00 | filing |
| 19 Apr 2021filed 20 Apr 2021 | OTLK Outlook TherapeuticsBiotechnology | SEC FORM 4 Bought | $18K10,000 at $1.82 | filing |
News
Outlook Therapeutics Names Greg DiPasquale Chief Commercial OfficerOTLK · manilatimes.net · 9 Oct 2026Outlook Therapeutics Highlights What the Appointment of New CFO Kevin Lundquist Means for the Company's Next Chapter in Virtual Investor DiscussionOTLK · manilatimes.net · 6 Oct 2026
0 headlines in the last 90 days name Yezan Munther Haddadin; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.